Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 553 matching trials from the live ClinicalTrials.gov search.
Conditions
Hepatitis B, Cirrhosis
Interventions
LdT (Telbivudine) and lamivudine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ascites, Liver Cirrhosis
Interventions
Satavaptan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Malvern, Pennsylvania
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Conditions
Cirrhosis
Interventions
Video Education, Text education
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Liver Fibrosis, Hepatic Cirrhosis
Interventions
AZD2389
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chandler, Arizona • Rialto, California • Atlanta, Georgia + 3 more
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Completed Not applicable Interventional Results available

Facilitating Communication Study

NCT03721952
Conditions
Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Multiple Organ Failure, Health Care Quality, Access, and Evaluation, Intensive Care Units, Palliative Care, Health Services, Palliative Care, Patient Care, Lung Diseases, Cerebrovascular Disorders, Brain Injuries
Interventions
Facilitator-Based Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Seattle, Washington
Conditions
Hepatitis C, Chronic, Cirrhosis
Interventions
Telaprevir, Boceprevir, Peg-IFN, Ribavirin
Drug
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Primary Biliary Cholangitis
Interventions
Part 1: LJN452, Part 1: Placebo, Part 2: LJN452 Dose level 1, Part 2: Placebo, Part 2: LJN452 Dose level 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Rialto, California • Miami, Florida • Atlanta, Georgia + 6 more
Conditions
Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions
Melatonin tablet 3 mg once daily, Thiamine
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Liver Fibrosis, Liver Diseases
Interventions
Sonographic SWE measurements with 4 different ultrasound systems
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Primary Biliary Cirrhosis
Interventions
Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Pasadena, California • Miami, Florida • Marietta, Georgia + 5 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Completed Phase 4 Interventional Results available

Prophylactic Antibiotics in Admitted Cirrhotics

NCT04218695
Conditions
Cirrhosis, Liver
Interventions
Ceftriaxone, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
Interventions
Gastric Emptying Breath Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cirrhosis, Congenital Heart Disease
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 21 more
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Conditions
Cirrhosis
Interventions
selenium, placebo
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Minimal Hepatic Encephalopathy
Interventions
Lactobacillus GG, Placebo
Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Cirrhosis
Interventions
Bumetanide, Furosemide
Drug
Lead sponsor
Stacy Johnson
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah